DHEA, boron and pregnenolone: what they add to the enclomiphene tablet

Why combine them at all?

Enclomiphene raises testosterone by increasing the brain's LH and FSH signals. The supporting ingredients are intended to supply raw materials or nudge other steps in hormone production. The idea is appealing: support the whole pathway rather than one step.

The reality is that combinations like this have not been tested as a package in clinical trials. Each ingredient's evidence has to be weighed on its own, and their combined effect is not known. Your clinician will be candid about that.

DHEA

Dehydroepiandrosterone is made mainly by the adrenal glands and declines with age. The body can convert it into testosterone and estrogen, which is why it is marketed for energy, libido and aging. In men, extra DHEA may be converted partly into estrogen as well as testosterone, which can matter when enclomiphene is already raising estradiol.

Evidence for benefit is limited. The Endocrine Society, for example, recommends against routine DHEA use in women, citing limited data on effectiveness and safety. Studies in men have been small and mixed. Possible side effects include acne, oily skin and hair changes. DHEA is a hormone and is prohibited in tested sport.

Boron

Boron is a trace mineral found in fruits, vegetables, nuts and legumes. The NIH Office of Dietary Supplements notes that boron is not classified as an essential nutrient because no clear biological function has been identified, although it may affect reproduction, bone formation, calcium metabolism and steroid hormones.

Research on boron and male hormones is small and short-term. The ODS sets an upper limit of 20 mg a day for adults and reports no known clinically relevant drug interactions; serious harm has mainly come from accidental ingestion of boric acid or borax, not from supplements at normal doses.

Pregnenolone

Pregnenolone is made from cholesterol and sits at the top of the steroid hormone pathway. The body converts it into progesterone, DHEA, cortisol, testosterone and estrogen, among others. Supplement marketing suggests that more pregnenolone means more of everything downstream.

Human clinical research on pregnenolone supplementation is sparse, and there is little evidence that it meaningfully raises testosterone or improves symptoms in men. Because it can feed into several hormones, its effects are hard to predict, which is one more reason for regular lab monitoring.

Who should be cautious

• Anyone with prostate cancer, breast cancer or another hormone-sensitive cancer, past or present
• Men with a raised PSA or significant urinary symptoms who have not been evaluated
• People with liver disease or a history of blood clots
• Men planning conception, who should ask whether the added hormones are appropriate
• Anyone already taking DHEA, pregnenolone or 'testosterone booster' supplements, to avoid doubling up
• Athletes subject to drug testing

Monitoring with a combined product

Because several ingredients can influence hormone levels, your clinician will usually check total testosterone, estradiol, LH, FSH, hematocrit and, depending on age, PSA a few weeks after starting and periodically afterward. If estradiol rises or side effects appear, your clinician may adjust your plan. If testosterone rises but you do not feel better, continuing is reconsidered rather than assumed.

If you would prefer enclomiphene without the added ingredients, ask your clinician whether that is available and appropriate for you.

How to judge whether it is helping

Because the extra ingredients have limited evidence, the most useful question is practical: are you feeling and functioning better, and are your labs safe? Before starting, agree with your clinician on two or three goals, such as energy through the afternoon, libido or recovery from exercise, and a review point, typically after a few months.

Keep brief notes on how you feel each week. At follow-up, compare them with your lab results. If your testosterone has risen but your goals have not moved, or if estradiol or hematocrit climb, your clinician may change or stop the plan.

Regulatory status and price

This is a compounded product made by a licensed U.S. pharmacy. Compounded medications are not FDA-approved, are not reviewed by the FDA for safety, effectiveness or quality, and are not interchangeable with branded products. Enclomiphene itself is not FDA-approved for any use. The ODT costs from $129/month, or $349 for three months ($116/month), with no membership fee, confirmed at the eligibility review; labs are priced separately.